Ultragenyx Seeks FDA Approval for Sanfilippo Gene Therapy After Long-Term Data
Event summary
- Ultragenyx submitted a BLA resubmission to the FDA for UX111 (rebisufligene etisparvovec) in January 2026, anticipating a six-month review period.
- Long-term data (up to 8.5 years) demonstrate sustained reductions in CSF-HS and meaningful improvements in cognitive, communication, and motor function in children with Sanfilippo syndrome Type A (MPS IIIA).
- Clinical improvements were observed across multiple developmental domains, with some patients reaching milestones not seen in untreated peers.
- The therapy, originally developed by Abeona Therapeutics, has received multiple designations including Fast Track, Rare Pediatric Disease, and PRIME.
The big picture
UX111 represents a significant advancement in gene therapy for rare, devastating diseases like Sanfilippo syndrome, a market with limited treatment options. The long-term data strengthens the case for gene therapy as a viable treatment modality for neurological disorders, but the high cost and complex logistics of gene therapy delivery pose ongoing challenges for broader adoption. This approval, if granted, could pave the way for similar gene therapy approaches targeting other rare genetic conditions.
What we're watching
- Regulatory Risk
- The FDA's review timeline and ultimate decision on the BLA resubmission will be critical, as a rejection could significantly impact Ultragenyx's valuation and future development plans.
- Market Adoption
- The therapy's success will depend on the ability to identify and treat patients early, requiring robust diagnostic capabilities and patient access programs given the disease's rarity and severity.
- Long-Term Efficacy
- Continued monitoring of patients beyond the 8.5-year mark is necessary to confirm the durability of the observed clinical benefits and identify any potential long-term adverse effects.
Related topics